Method for detecting immune efficacy and method of treating a cancer
OwnerChun-Hsuan HOinventor
Life of this patent
Estimating the term…
Abstract
In some embodiments of the present disclosure, a method for detecting immune efficacy is provided, including: generating quantity percentages of the plurality of T cell subgroups in the lymphocytes and quantity percentages of the nature killer cell subgroups in the lymphocytes to obtain actual percentages of the plurality of T cell subgroups and actual percentages of the nature killer cell subgroups; and judging whether immune efficacy is normal according to the actual percentages of the plurality of T cell subgroups and the actual percentages of the nature killer cell subgroups. Some embodiments of the present disclosure further provide a method of treating a cancer of an individual by regulating an actual number of a total number of T cells or nature killer cells.
Claims38
A method for detecting immune efficacy, comprising:
- providing an in vitro sample of an individual, wherein the in vitro sample comprises a plurality of lymphocytes;
- classifying the plurality of lymphocytes into a plurality of T cell subgroups based on expression or not of a plurality of first antigens, and classifying the plurality of lymphocytes into a plurality of natural killer cell subgroups based on expression or not of a plurality of second antigens, wherein the plurality of first antigens comprise CD28, and the plurality of second antigens comprise CD16;
- generating quantity percentages of the plurality of T cell subgroups in the plurality of lymphocytes and quantity percentages of the plurality of nature killer cell subgroups in the plurality of lymphocytes to obtain actual percentages of the plurality of T cell subgroups and actual percentages of the plurality of nature killer cell subgroups;
- and
- judging whether the actual percentage of each of the plurality of T cell subgroups meets a T cell subgroup reference range, and judging whether the actual percentage of each of the plurality of natural killer cell subgroups meets a natural killer cell subgroup reference range,
- when the actual percentage of each of the plurality of T cell subgroups meets the T cell subgroup reference range and the actual percentage of each of the plurality of natural killer cell subgroups meets the natural killer cell subgroup reference range, the immune efficacy of the individual is judged normal.
A system for detecting immune efficacy, comprising a processor and a memory, and the memory storing a plurality of computer program instructions, and the computer program instructions, when executed by the processor, causing the processor to implement following steps:
- accessing an in vitro sample data of an individual, the in vitro sample data comprising a plurality of sample cell surface antigen data;
- generating a plurality of T cell subgroup count data and a plurality of natural killer cell subgroup count data according to the in vitro sample data using a cell subgroup database, wherein the cell subgroup database comprises a T cell subgroup classification information and a natural killer cell subgroup classification information, and the T cell subgroup classification information comprises a classification index according to expression or not of a plurality of first antigens, wherein the plurality of first antigens comprise CD28, and the natural killer cell subgroup classification information comprises a classification index according to expression or not of a plurality of second antigens, wherein the plurality of second antigens comprise CD16;
- and
- generating an immune efficacy data according to the plurality of T cell subgroup count data and the plurality of natural killer cell subgroup count data using an immune efficacy evaluation database, wherein the immune efficacy evaluation database comprises a plurality of T cell subgroup reference range data and a plurality of natural killer cell subgroup reference range data.
A method of treating a cancer of an individual by a plurality of lymphocytes, wherein the plurality of lymphocytes comprise a plurality of T cells, a plurality of natural killer cells or a combination thereof, and the method comprises:
- (a) generating a deviation value of a total number of T cells between an actual number of the total number of T cells and a theoretical range of the total number of T cells, and generating a deviation value of a total number of nature killer cells between an actual number of the total number of nature killer cells and a theoretical range of the total number of nature killer cells;
- and
- (b) administering a pharmaceutical composition comprising the plurality of T cells to the individual based on the deviation value of the total number of T cells to allow the actual number of the total number of T cells of the individual to fall within the theoretical range of the total number of T cells, and
- administering the pharmaceutical composition comprising the plurality of nature killer cells to the individual based on the deviation value of the total number of nature killer cells to allow the actual number of the total number of nature killer cells of the individual to fall within the theoretical range of the total number of nature killer cells.
A method of treating a cancer of an individual by a plurality of nature killer cells, comprises:
- (a) determining an actual value of a natural killer cell cytotoxicity of the plurality of natural killer cells, wherein the actual value of the natural killer cell cytotoxicity is generated by following steps:
- co-culturing the plurality of natural killer cells with a plurality of cancer cells with a quantitative ratio;
- and
- generating a quantity percentage of the cancer cells that die to obtain the actual value of the natural killer cell cytotoxicity;
- (b) generating a deviation value of a natural killer cell cytotoxicity between an actual value of the natural killer cell cytotoxicity and a theoretical range of the natural killer cell cytotoxicity based on the actual value of the natural killer cell cytotoxicity and the theoretical range of the natural killer cell cytotoxicity;
- (c) administering a pharmaceutical composition comprising the plurality of nature killer cells to the individual based on the deviation value of the natural killer cell cytotoxicity to allow the actual value of the natural killer cell cytotoxicity of the individual to fall within the theoretical range of the natural killer cell cytotoxicity.
Dependencies are inferred from the claim text.